Among patients who discontinued enfortumab vedotin due to an ongoing response or toxicity, 57% were treatment-free and alive 1 year later.
Joy Li, MD
Advertisement
Articles by Joy Li, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Combatting Toxicities and Leveraging Novel Therapies in Lung Cancer Care
2
Navigating Oligometastasis and Oligoprogression in Stage IV Breast Cancer
3
Elucidating Treatment Selection for Metastatic HSPC at ASCO GU 2026
4
Assessing Thyroid Cancer Risk With GLP-1 Therapy
5